摘要
背景:帕金森病(PD)是一种神经退行性疾病,其特征在于黑质致密部(SNpc)内多巴胺能神经元的丧失。 尽管进行了许多研究,但仍无法治愈这种疾病。 左旋多巴是PD的第一线治疗,但长期使用它会导致运动障碍和运动障碍。 多巴胺激动剂是治疗PD的优选选择。 它们具有神经保护作用,但有副作用。 目的:我们的目的是回顾已经对多巴胺受体激动剂开展的工作以及减少其副作用的未来可能性。 结论:在这篇综述中,我们强调了多巴胺的代谢,不同类型的多巴胺激动剂及其特性和可能的副作用。
关键词: 神经退行性疾病,多巴胺,激动剂,代谢,神经递质,中枢神经系统。
图形摘要
Current Drug Targets
Title:Dopamine: Agonists and Neurodegenerative Disorders
Volume: 19 Issue: 14
关键词: 神经退行性疾病,多巴胺,激动剂,代谢,神经递质,中枢神经系统。
摘要: Background: Parkinson’s disease (PD) is a neurodegenerative disease characterized by the loss of dopaminergic neurons within the substantia nigra pars compacta (SNpc). Despite many researches, there is still no cure for this disease. Levodopa is the first line treatment of PD, but the long term use of it leads to motor impairments and dyskinesias. The dopamine agonists are the preferred choice for the treatment of PD. They are neuroprotective in nature but have side effects.
Objective: Our aim was to review the work that has been carried out on dopamine agonists and the future possibilities to reduce their side effects.
Conclusion: In this review, we highlighted the metabolism of dopamine, different types of dopamine agonists with their properties and possible side effects.
Export Options
About this article
Cite this article as:
Dopamine: Agonists and Neurodegenerative Disorders, Current Drug Targets 2018; 19 (14) . https://dx.doi.org/10.2174/1389450118666171117124340
DOI https://dx.doi.org/10.2174/1389450118666171117124340 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Related Journals
Related Books
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Kynurenines in the Central Nervous System: Recent Developments
Central Nervous System Agents in Medicinal Chemistry Protein Homeostasis as a Therapeutic Target for Diseases of Protein Conformation
Current Topics in Medicinal Chemistry Exploring the Role of Stem Cell Therapy in Treating Neurodegenerative Diseases: Challenges and Current Perspectives
Current Stem Cell Research & Therapy Nicotinic Receptors and the Treatment of Attentional and Cognitive Deficits in Neuropsychiatric Disorders: Focus on the α7 Nicotinic Acetylcholine Receptor as a Promising Drug Target for Schizophrenia
Central Nervous System Agents in Medicinal Chemistry Substance Abuse and Movement Disorders: Complex Interactions and Comorbidities
Current Drug Abuse Reviews Current Limitations in the Treatment of Parkinson’s and Alzheimer’s Diseases: State-of-the-Art and Future Perspective of Polymeric Carriers
Current Medicinal Chemistry Monoamine Oxidase Inhibitors Extracted from Tobacco Smoke as Neuroprotective Factors for Potential Treatment of Parkinson`s Disease
CNS & Neurological Disorders - Drug Targets Cannabidiol and Sodium Nitroprusside: Two Novel Neuromodulatory Pharmacological Interventions to Treat and Prevent Psychosis
CNS & Neurological Disorders - Drug Targets Advances in Mucomodulator Therapy for Treatment of Excess Airway Mucus in Patients with Asthma, Chronic Obstructive Pulmonary Disease and Cystic Fibrosis
Recent Patents on Materials Science Cannabinoids and Neuro-Inflammation: Regulation of Brain Immune Response
Recent Patents on CNS Drug Discovery (Discontinued) Basic Pharmacology of NMDA Receptors
Current Pharmaceutical Design Antipsychotics in Obsessive-Compulsive Disorder
Current Psychiatry Reviews Current Research on Opioid Receptor Function
Current Drug Targets Drug Therapy in Schizophrenia
Current Pharmaceutical Design Neuroprotection and Hypothermia in Infants and Children
Current Drug Targets Theories and Treatment of Drug Dependency: A Neurochemical Perspective
Current Molecular Pharmacology Gene Therapy for Parkinsons Disease: Progress and Challenges
Current Gene Therapy The Dopamine D3 Receptor: A Therapeutic Target for the Treatment of Neuropsychiatric Disorders
CNS & Neurological Disorders - Drug Targets A Review of Current Strategies for Treatment Resistant Obsessive-Compulsive Disorder
Current Drug Therapy Intrahypothalamic Administration of Modafinil Increases Expression of MAP-Kinase in Hypothalamus and Pons in Rats
CNS & Neurological Disorders - Drug Targets